This international prize, established in 2002, encourages the work of promising young neurobiologists by providing support in the early stages of their careers. It is awarded annually for the most outstanding neurobiological research by a young scientist, as described in a 1,000-word essay based on research performed during the past three years.
The winner will receive US$25,000 and publication of his or her essay in Science. The essays of up to three finalists will also be published on Science Online.
Researchers who are 35 or younger are invited to apply by 15 June. The prizewinner will be selected by a committee of independent experts in the field, chaired by Science’s senior editor, Peter Stern.
The 2010 prize was won by Christopher Gregg, Postdoctoral Fellow at Harvard University for his research on maternal and paternal gene expression in the brain.
2011 Neurobiology Prize open for entries
Organised by Eppendorf and Science journal
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies